Evidence map›Paper›PMID 29507667›Full record

ArticleOncotarget2018

Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer.

Kiley A Knapp, Eusebio S Pires, Sara J Adair, Arabinda Mandal, Anne M Mills, Walter C Olson, Craig L Slingluff, J Thomas Parsons, Todd W Bauer, Timothy N Bullock and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Kiley A KnappDepartment of Pathology, The School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Eusebio S PiresDepartment of Cell Biology, The School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Sara J AdairDepartment of Surgery, The School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Arabinda MandalDepartment of Cell Biology, The School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Anne M MillsDepartment of Pathology, The School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Walter C OlsonDepartment of Surgery, The School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Craig L SlingluffDepartment of Surgery, The School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
J Thomas ParsonsDepartment of Microbiology, The School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Todd W BauerDepartment of Surgery, The School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Timothy N BullockDepartment of Pathology, The School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
John C HerrDepartment of Pathology, The School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
University of Virginia · US

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1M
NCI NIH HHS L30 CA124093NCI NIH HHS P30 CA044579
6 · The paper itself

Abstract

Successful therapeutic options remain elusive for pancreatic cancer. The exquisite sensitivity and specificity of humoral and cellular immunity may provide therapeutic approaches if antigens specific for pancreatic cancer cells can be identified. Here we characterize SAS1B (ovastacin,

Indexed as

antibody-drug conjugateASTL/SAS1B/ovastacinpancreatic cancer biomarkersurface cancer-oocyte antigentargeted immunotherapy

Identifiers

PMID29507667
PMCPMC5823626
OpenAlexW2782436341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.